2019

The PFF Scholars program focuses on engaging early-career investigators in their emerging research in the field of pulmonary fibrosis. With the goal of advancing research that could translate into successful therapies for PF, the PFF Scholars program is designed to support and enable promising researchers to obtain independent funding and continue their cutting- edge research. Scholars will receive up to $50,000 over a two-year period.

Andrew Haak, PhD

Apr 21, 2021, 09:22 AM
Title : Andrew Haak, PhD
First Name : Andrew
Middle Name :
Last Name : Haak
Position :
University : Mayo Clinic
Proposal Title :
Proposal Funder :
While attending Minnesota State University Moorhead, Andrew joined the combined laboratory of Drs. Joseph Provost and Mark Wallert where he investigated the role of the sodium hydrogen (NHE1) exchanger in non-small cell lung cancer migration, proliferation, and anchorage independent growth. For his doctoral work at The University of Michigan, he studied with Dr. Richard Neubig, an expert in the field of pharmacology and drug discovery. Following a high-throughput screening campaign, Andrew developed a potent and selective inhibitor of MRTF which effectively blocked in vivo melanoma lung metastasis and dermal fibrosis. This work led him to focus his postdoctoral research on pulmonary fibrosis. Andrew joined Dr. Tschumperlin’s group at The Mayo Clinic with the idea of combining Dr. Tschumperlin’s expertise in mechanosignaling and pulmonary fibrosis with Andrew’s background in pharmacology and drug discovery to identify and target novel mechanisms of fibroblast activation that could dramatically impact the outcome of this disease.
Load more comments
Comment by from